Best of ASCO 2024, Seattle

Seattle, WA US
June 15, 2024 to June 16, 2024

This CME-accredited oncology conference, Best of ASCO 2024, Seattle, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.

Expert faculty will provide a comprehensive overview of practice-changing abstracts presented at the 2024 ASCO® Annual Meeting (ASCO2024) in June 2024. The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in the field. Expert faculty will place abstract findings from ASCO2024 into clinical contexts and discuss how the results may change the current standard of care. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Oncology residents/fellows
  • Oncology NPs/PAs
  • Oncology pharmacists
  • Oncology nurses

Organizing Committee: 

Course Director:

Binay Shah, MD, MHA - Binaytara Foundation

Co-Chairs:

David Zhen, MD - Fred Hutchinson Cancer Center, University of Washington

Petros Grivas, MD, PhD - Fred Hutchinson Cancer Center, University of Washington

VENUE INFORMATION

If you are attending this meeting and need to reserve a hotel room, please reserve your room at The Westin Seattle by clicking here to take advantage of the discounted group rate of $209 per night plus applicable taxes and fees.

Please book your room by Thursday, May 23, 2024 to receive the discounted group rate.

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Discuss new and updated treatment options for patients with hematologic malignancies and solid tumors
  2. Identify side effects, indications, and contra-indications of therapies used to diagnose and treat cancers
  3. Explain how to effectively manage side-effects associated with cancer treatment
  4. Review abstracts presented at ASCO® 2024 and discuss their application in clinical settings

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 11.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 11.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 11.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.00 Contact Hours.
Course opens: 
11/07/2023
Course expires: 
09/06/2024
Event starts: 
06/15/2024 - 8:00am PDT
Event ends: 
06/16/2024 - 12:15pm PDT
Cost:
$350.00

DAY 1 - JUNE 15TH, 2024


All times below are listed in Pacific Standard Time (PST).

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits

08:00 AM – 08:05 AM  Welcome


08:05 AM – 09:35 AM  Session 1 - Breast Cancer

Session Chair: Hope Rugo, MD, FASCO

08:05 AM  08:35 AM  Early-Stage Breast Cancer - Erin Cobain, MD

08:35 AM  09:05 AM  Metastatic Breast Cancer 1 (Hormone Receptor-Positive) - Hope Rugo, MD, FASCO

09:05 AM – 09:35 AM  Metastatic Breast Cancer 2 (HER2+ve and Triple-Negative Breast Cancer) - Vidhya Nair, DO


09:35 AM – 09:45 AM  Break & Exhibits


09:45 AM – 11:15 AM  Session 2 - Thoracic Oncology

Session Chair: Keith Eaton, MD

09:45 AM  10:15 AM  Early-Stage Lung Cancer - Diane Tseng, MD

10:15 AM – 10:45 AM  Metastatic Lung Cancer - Angel Qin, MD

10:45 AM – 11:15 AM  Small-Cell Lung Cancer - Siddhartha Devarakonda, MD


11:15 AM – 11:45 AM  Session 3 - Case-based Presentations 1

Session Chair: Wayne Gao, MD, PhD

11:15 AM – 11:30 AM  Case 1: Breast Cancer - Xiaowen (Wendy) Wang, MD, PhD

11:30 AM  11:45 AM  Case 2: Thoracic Oncology - Nicholas Giustini, MD


11:45 AM  12:15 PM  Access to Cancer Care in LMIC - Binay Shah, MD, MHA


12:15 PM – 01:15 PM  Lunch & Exhibits

12:30 PM – 01:15 PM  Product Theater Sponsored by Exelixis

Presentation Title: An Exelixis Product for the Clinical Management of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma

Speaker: Suresh Ratnam, MD, FACP, MRCP | Texas Oncology 

* Non-CME Activity *


01:15 PM – 03:15 PM  Session 4 - General Oncology

Session Chair: Kelly Paulson, MD, PhD

01:15 PM  01:45 PM  Sarcoma Updates - Michael Wagner, MD

01:45 PM  02:15 PM  Brain tumor Updates - Vyshak Venur, MD

02:15 PM  02:45 PM  Head neck Cancer - Paul Swieciki, MD

02:45 PM  03:15 PM  Gynecologic Cancer - Kalyan Banda, MD


03:15 PM – 03:30 PM  Break & Exhibits


03:30 PM – 05:00 PM  Session 5 - Hematologic Malignancies

Session Chair: Mohamed Sorror, MD, MSc

03:30 PM  04:00 PM  MDS/Leukemias - Anna Halpern, MD

04:00 PM  04:30 PM  Multiple Myeloma - Mary Kwok, MD

04:30 PM  05:00 PM  Lymphoma & CLL - Mazyar Shadman, MD, MPH


 

DAY 2 - JUNE 16TH, 2024
 

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 09:00 AM  Session 6 - Case-Based Presentations 2

Session Chair: Camille Puronen, MD, MPH

08:00 AM  08:15 AM  Case 1: Gynecologic cancer - Kalyan Banda, MD 

08:15 AM  08:30 AM  Case 2: GU Cancer - Li Zhang, MD

08:30 AM  08:45 AM  Case 3: GI Cancer - David Zhen, MD

08:45 AM  09:00 AM  Case 4: Hematologic Malignancies - Andrew Portuguese, MD


09:00 AM – 10:30 AM  Session 7 - GI Cancer

Session Chair: David Zhen, MD

09:00 AM  09:30 AM  Colorectal Cancer - Stacey Cohen, MD

09:30 AM  10:00 AM  Hepatobiliary and Pancreatic Malignancies - Andrew Coveler, MD

10:00 AM  10:30 AM  Upper GI Cancer - Ronan Hsieh, MD, MS


10:30 AM – 11:15 AM  Break & Exhibits

10:30 AM – 11:15 AM  Product Theater Sponsored by Merck

Topic: A Treatment Option for Adult Patients With Locally Advanced or Metastatic Urothelial Cancer

Speaker: Nitin Rohatgi, MD, Shutter Health

Learning objectives

Present an overview of urothelial cancer
Review efficacy and safety data for a treatment option for adult patients with locally advanced or metastatic urothelial cancer
Understand how to manage potential select adverse reactions associated with this treatment option

* Non-CME Activity *


11:15 AM – 12:45 PM  Session 8 - Genitourinary Cancer

Session Chair: Petros Grivas, MD, PhD

11:15 AM  11:45 AM  Prostate Cancer - Mike Schweizer, MD

11:45 AM  12:15 PM  Bladder Cancer - Todd Yezefski, MD, MS

12:15 PM – 12:45 PM  Kidney Cancer - Evan Hall, MD, MPhil


12:45 PM  Adjourn

The Westin Seattle
1900 5th Ave
Seattle, WA 98101
United States

If you are attending this meeting and need to reserve a hotel room, please reserve your room at The Westin Seattle by clicking here to take advantage of the discounted group rate of $209 per night plus applicable taxes and fees.

Please book your room by Thursday, May 23, 2024 to receive the discounted group rate.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

David Zhen, MD

has a financial relationship (Grant Or Contract) with Astra Zeneca;.
has a financial relationship (Grant Or Contract) with Eli Lilly;.
has a financial relationship (Independent contractor) with Jazz Pharmaceuticals/Zymeworks, Inc;.
has a financial relationship (Grant Or Contract) with Daiichi-Sankyo;.
has a financial relationship (Grant Or Contract) with Cornerstone Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Legend Biotech;.
has a financial relationship (Grant Or Contract) with Seagen;.
has a financial relationship (Grant Or Contract) with Bristol Meyers Squibb;.
has a financial relationship (Grant Or Contract) with Roche/Genentech;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Grant Or Contract) with Ipsen;.
Session Chair(s)

Keith Eaton, MD, PhD

has no relevant financial relationships to disclose at this time.

Weiqiang Gao

has no relevant financial relationships to disclose at this time.

Kelly Paulson, MD, PhD

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

vyshak Alva Venur

has no relevant financial relationships to disclose at this time.

Kalyan Banda

has a financial relationship (Other) with Pfizer ;.
has a financial relationship (Other) with Regeneron;.
has a financial relationship (Other) with MorphoSys;.
has a financial relationship (Other) with Eli Lily ;.
has a financial relationship (Other) with Kineta;.

Erin Cobain

has a financial relationship (Independent contractor) with Biotheranostics;.
has a financial relationship (Independent contractor) with Daiichi Sankyo;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with Epic Sciences;.
has a financial relationship (Grant Or Contract) with Novartis Pharmaceuticals;.

Stacey Cohen

has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with Delcath;.

Andrew Coveler, MD

has a financial relationship (Independent contractor) with AbGenomics;.
has a financial relationship (Independent contractor) with Actuate;.
has a financial relationship (Independent contractor) with Astrazeneneca;.
has a financial relationship (Independent contractor) with Mirati;.
has a financial relationship (Travel) with Nucana;.
has a financial relationship (Independent contractor) with Amgen;.
has a financial relationship (Independent contractor) with Seagen;.

Siddhartha Devarakonda, MBBS, MD

has a financial relationship (Other) with Jazz;.
has a financial relationship (Other) with Daiichi-Sankyo;.
has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with Eli Lilly;.
has a financial relationship (Other) with Takeda;.
has a financial relationship (Other) with Genentech;.
has a financial relationship (Other) with Apollomics;.

Evan Hall, MD, MPhil

has a financial relationship (Other) with Bristol-Myers-Squibb;.
has a financial relationship (Other) with Replimune;.
has a financial relationship (Other) with NiKang;.
has a financial relationship (Other) with ImCheck;.
has a financial relationship (Other) with Nektar;.

Anna Halpern, MD

has a financial relationship (Other) with Jazz pharmaceuticals;.
has a financial relationship (Other) with Incytes Pharmaceuticals;.
has a financial relationship (Other) with Bayer;.
has a financial relationship (Other) with Karyopharm Therapeutics;.
has a financial relationship (Other) with Abbvie;.
has a financial relationship (Other) with Gilead Sciences;.
has a financial relationship (Grant Or Contract) with Disc Medicine;.
has a financial relationship (Other) with Imago Biosciences;.
has a financial relationship (Grant Or Contract) with Merck;.

Ronan Hsieh, MD, MS

has no relevant financial relationships to disclose at this time.

Mary Kwok

has a financial relationship (Independent contractor) with BMS;.

Angel Qin, MD

has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Summit Therapeutics;.

Hope Rugo

has a financial relationship (Grant Or Contract) with Astellas Pharma Inc.;.
has a financial relationship (Professional Services) with Eisai;.
has a financial relationship (Grant Or Contract) with Stemline;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Pionyr Immunotherapeutics;.
has a financial relationship (Grant Or Contract) with Gilead Sciences, Inc;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Daiichi Sankyo, Inc;.
has a financial relationship (Grant Or Contract) with OBI Pharma;.
has a financial relationship (Grant Or Contract) with GlaxoSmithKline;.
has a financial relationship (Professional Services) with NAPO;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with F. Hoffmann-La Roche AG/Genentech, Inc.;.
has a financial relationship (Grant Or Contract) with Sermonix Pharmaceuticals Inc.;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Professional Services) with Mylan;.
has a financial relationship (Grant Or Contract) with Veru Inc. ;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Grant Or Contract) with Taiho Oncology, Inc.;.

Michael Schweizer, MD

has a financial relationship (Independent contractor) with Sanofi;.

Mazyar Shadman, MD,MPH

has a financial relationship (Professional Services) with Vincerx ;.
has a financial relationship (Professional Services) with Eli Lily ;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Employment) with BMS;.
has a financial relationship (Professional Services) with Kite Pharma ;.
has a financial relationship (Professional Services) with Nurix;.
has a financial relationship (Professional Services) with Mustang Bio ;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Janssen ;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with MorphoSys/Incyte;.
has a financial relationship (Stock Options) with Koi Biotherapeutics;.
has a financial relationship (Professional Services) with Fate therapeutics;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Genmab;.

Paul Swiecicki, M.D.

has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with CDR Life;.
has a financial relationship (Independent contractor) with Elevar Therapeutics;.
has a financial relationship (Independent contractor) with Regeneron;.
has a financial relationship (Independent contractor) with Remix Therapeutics;.

Diane Tseng, MD PhD

has a financial relationship (Intellectual Property Other) with Gilead Sciences;.
has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with Gilead Sciences;.

Michael Wagner

has a financial relationship (Professional Services) with PharmaEssentia;.
has a financial relationship (Professional Services) with Aadi;.
has a financial relationship (Professional Services) with Deciphera;.
has a financial relationship (Travel) with Adaptimmune;.

Todd Yezefski

has no relevant financial relationships to disclose at this time.
Case Presenter(s)

Nicholas Giustini, MD

has a financial relationship (Other) with Curio Science;.

Xiaowen Wang, MD, PhD

has no relevant financial relationships to disclose at this time.

Li Zhang, MD

has no relevant financial relationships to disclose at this time.
Moderator(s)

Camille Puronen, MD, MPH

has no relevant financial relationships to disclose at this time.

Hope Rugo

has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Pionyr Immunotherapeutics;.
has a financial relationship (Grant Or Contract) with Astellas Pharma Inc.;.
has a financial relationship (Professional Services) with Eisai;.
has a financial relationship (Grant Or Contract) with Stemline;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Daiichi Sankyo, Inc;.
has a financial relationship (Grant Or Contract) with OBI Pharma;.
has a financial relationship (Grant Or Contract) with Gilead Sciences, Inc;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with F. Hoffmann-La Roche AG/Genentech, Inc.;.
has a financial relationship (Grant Or Contract) with Sermonix Pharmaceuticals Inc.;.
has a financial relationship (Grant Or Contract) with GlaxoSmithKline;.
has a financial relationship (Professional Services) with NAPO;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Grant Or Contract) with Taiho Oncology, Inc.;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Professional Services) with Mylan;.
has a financial relationship (Grant Or Contract) with Veru Inc. ;.

Mohamed Sorror

has a financial relationship (Professional Services) with JAZZ PHARMACEUTICALS CANADA;.

Available Credit

  • 11.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 11.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 11.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.00 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.